Interactions and monitoring of antipsychotic drugs

Handbook of Experimental Pharmacology

Volumn 212, Issue , 2012, Pages 241-265

  Hiemke, Christoph ^a   Pfuhlmann, Bruno ^b  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Cytochrome P450; Drug drug interactions; Pharmacodynamics; Pharmacokinetics; Plasma concentration; Therapeutic drug monitoring

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; BENPERIDOL; BIPERIDEN; BROMPERIDOL; CARBAMAZEPINE; CHLORPROMAZINE; CHLORPROTHIXENE; CHOLINERGIC RECEPTOR; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DOPAMINE 2 RECEPTOR; FLUPHENAZINE; HISTAMINE H1 RECEPTOR; LEVOMEPROMAZINE; MELPERONE; NEUROLEPTIC AGENT; PALIPERIDONE; PERPHENAZINE; RISPERIDONE; THIORIDAZINE; TRIHEXYPHENIDYL; UNINDEXED DRUG; VERAPAMIL; ZIPRASIDONE;

AKATHISIA; ARTICLE; COGNITIVE DEFECT; COMORBIDITY; CONSTIPATION; DELIRIUM; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; GLAUCOMA; HEART DISEASE; HEART VENTRICLE ARRHYTHMIA; HUMAN; LIBIDO; METABOLIC DISORDER; MONOTHERAPY; NAUSEA; PHARMACODYNAMICS; PRIORITY JOURNAL; QT PROLONGATION; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SINUS TACHYCARDIA; TACHYCARDIA; THERMOREGULATION; TORSADE DES POINTES; URINE RETENTION; VOMITING; WEIGHT GAIN; XEROSTOMIA; DRUG COMBINATION; DRUG INTERACTION; REVIEW;

ANTIPSYCHOTIC AGENTS; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; HUMANS;

EID: 84870194213     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-25761-2_10     Document Type: Article

References (70)

1. Baptista T, Zárate J, Joober R, Colasante C, Beaulieu S, Páez X, Hernández L (2004) Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr Drug Targets 5:279-299 (Pubitemid 38372313)
2. Barnes TR, Paton C (2011) Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs 25:383-399
3. Bender S, Grohmann R, Engel RR, Degner D, Dittmann Balcar A, Rüther E (2004) Severe adverse drug reactions in psychiatric inpatients treated with neuroleptics. Pharmacopsychiatry 37(1): S46-S53 (Pubitemid 38658330)
4. Benet LZ, Hoener B-A (2002) Changes in plasma binding have little clinical relevance. Clin Pharmacol Ther 71:115-121 (Pubitemid 34271114)
5. Bondolfi G, Morel F, Crettol S, Rachid F, Baumann P, Eap CB (2005) Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Ther Drug Monit 27:539-543 (Pubitemid 41098833)
6. Cascorbi I (2011) P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Handb Exp Pharmacol 201:261-283
7. Castberg I, Skogvoll E, Spigset O (2007) Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. J Clin Psychiatry 68:1540-1545 (Pubitemid 350073402)
8. Chew ML, Mulsant BH, Poloock BG, Lehman ME, Greenspan A, Mahmoud RA, Kirshner MA, Sorisio DA, Bies RR, Gharabawi G (2008) Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc 56:1333-1341
9. Cole ML, Trigoboff E, Demler TL, Opler LA (2010) Impact of smoking cessation on psychiatric inpatients treated with clozapine or olanzapine. J Psychiatr Pract 16:75-81
10. Crumb WJ Jr, Ekins S, Sarazan RD, Wikel JH, Wrighton SA, Carlson C, Beasley CM Jr (2006) Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis. Pharm Res 23:1133-1143 (Pubitemid 43946136)
11. Dobrinas M, Cornuz J, Oneda B, Kohler Serra M, Puhl M, Eap CB (2011) Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility. Clin Pharmacol Ther 90:117-125
12. DeGorter MK, Xia CQ, Yang JJ, Kim RB (2012) Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol 52:249-273
13. Dürr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K (2000) St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68:598-604 (Pubitemid 32059985)
14. Faber MS, Jetter A, Fuhr U (2005) Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol 97:125-134 (Pubitemid 41291208)
15. Farde L, Nordström AL, Wiesel F-A, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544
16. Farde L, Wiesel FA, Halldin C, Sedvall G (1988) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45:71-76 (Pubitemid 18018572)
17. Faries D, Ascher-Svanum H, Zhu B, Correll C, Kane J (2005) Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 5:26
18. Freudenreich O, Goff DC (2002) Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 106:323-330 (Pubitemid 35176874)
19. Ghadirian AM, Annable L, Bélanger MC, Chouinard G (1996) A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients. J Clin Psychiatry 57:22-28
20. Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, de Hert M, Falkai P, Kapur S, Leucht S, Licht R, Naber D, O'Keane V, Papakostas G, Vieta E, Zohar J (2009) Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol 19:520-532
21. Gross G, Drescher K (2012) The role of dopamine D3 receptors for antipsychotic activity and cognitive functions. In: Geyer M, Gross G (eds) Novel antischizophrenia treatments, vol 213, Handbook of Experimental Pharmacology. Springer, Berlin
22. Gründer G, Carlsson A, Wong DF (2003) Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 60:974-977 (Pubitemid 37222078)
23. Gründer G, Hiemke C, Paulzen M, Veselinovic T, Vernaleken I (2011) Therapeutic plasma concentrations of antidepressants and antipsychotics: lessons from PET imaging. Pharmacopsychiatry 44:236-248
24. Heal DJ, Gosden J, Jackson HC, Cheetham SC, Smith SL (2012) In: Gross G, Geyer M (ed) Current antipsychotics. Handbook of Experimental Pharmacology, vol 212. Springer, Berlin, pp xxx-xxx
25. Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Jaquenoud Sirot E, Kirchherr H, Laux G, Lutz UC, Messer T, Müller MJ, Pfuhlmann B, Rambeck B, Riederer P, Schoppek B, Stingl J, Uhr M, Ulrich S, Waschgler R, Zernig G (2011) AGNP consensus guidelines for therapeutic drug monitoring in psychiatry - update 2011. Pharmacopsychiatry 44:195-235
26. Jecel J, Michel TM, Gutknecht L, Schmidt D, Pfuhlmann B, Jabs BE (2005) Toxic clozapine serum levels during acute urinary tract infection: a case report. Eur J Clin Pharmacol 60:909-910 (Pubitemid 40386164)
27. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL (2008) N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 33:2303-2312
28. Jerling M, Lindström L, Bondesson U, Bertilsson L (1994) Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 16:368-374 (Pubitemid 24222520)
29. Juurlink DN, Mamdani MM, Kopp A, Laupacis A, Redelmeier DA (2003) Drug-drug interactions among elderly patients hospitalized for drug toxicity. J Am Med Assoc 289:1652-1658 (Pubitemid 37430270)
30. Kannakeril PC, Roden DM (2007) Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol 22:39-43 (Pubitemid 44901054)
31. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P (2000) A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 57:553-559 (Pubitemid 30349435)
32. Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, Houle S (1998) 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 155:921-928 (Pubitemid 28307604)
33. Kirschbaum KM, Uhr M, Holthoewer D, Namendorf C, Pierzik C, Hiemke C, Schmitt U (2011) Pharmacokinetics of acute and subchronic aripiprazole in P-glycoprotein deficient mice. Neuropharmacology 2010(59):474-479
34. Köhler GI, Bode-Böger SM, Busse R, Hoopmann M, Welte T, Böger RH (2000) Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 38:504-513
35. Kr of guinea-pig cardiomyocytes by the antipsychotic drug clozapine. Br J Pharmacol 148:499-509 (Pubitemid 43882086)
36. Letsas KP, Sideris A, Kounas SP, Efremidis M, Korantzopoulos P, Kardaras F (2006) Drug-induced QT interval prolongation after ciprofloxacin administration in a patient receiving olanzapine. Int J Cardiol 109:273-274 (Pubitemid 44399739)
37. Lowe EJ, Ackman ML (2010) Impact of tobacco smoking cessation on stable clozapine or olanzapine treatment. Ann Pharmacother 44:727-732
38. Lu ML, Lane HY, Chen KP, Jann MW, Su MH, Chang WH (2000) Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J Clin Psychiatry 61:594-599
39. Lynch T, Price A (2007) The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician 76:391-396 (Pubitemid 47219454)
40. Ma X, Idie J, Gonzalez FJ (2008) The pregnane X receptor: from bench to bedside. Expert Opin Drug Metab Toxicol 4:895-908
41. Medori R, Mannaert E, Gründer G (2006) Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable. Eur Neuropsychopharmacol 16:233-240
42. Misawa F, Shimizu K, Fujii Y, Miyata R, Koshiishi F, Kobayashi M, Shida H, Oguchi Y, Okumura Y, Ito O, Kayama H (2011) Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross sectional study. BMC Psychiatry 11:118
43. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M (2011) Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders - A systematic review and meta-analysis. Schizophr Bull 2011 [Epub ahead of print]
44. Moons T, de Roo M, Claes S, Dom G (2011) Relationship between P-glycoprotein and second-generation antipsychotics. Pharmacogenomics 12:1193-1211
45. Nakamura A, Mihara K, Nagai G, Suzuki T, Kondo T (2009) Pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole in patients with schizophrenia. Ther Drug Monit 31:575-578
46. Newcomer JW (2007) Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 68(suppl 1):20-27
47. Nickl-Jockschat T, Paulzen M, Schneider F, Grözinger M (2009) Drug interaction can lead to undetectable serum concentrations of quetiapine in the presence of carbamazepine. Clin Neuropharmacol 32(1):55
48. Pang X, Cheng J, Krausz KW, Guo DA, Gonzalez FJ (2011) Pregnane X receptor-mediated induction of Cyp3a by black cohosh. Xenobiotica 41:112-123
49. Pfuhlmann B, Hiemke C, Unterecker S, Burger R, Schmidtke A, Riederer P, Deckert J, Jabs B (2009) Toxic clozapine serum levels during inflammatory reactions. J Clin Psychopharmacol 29:392-394
50. Richelsen E, Souder T (2000) Binding of antipsychotic drugs to human brain receptors. Focus on newer generation compounds. Life Sci 68:29-39
51. Roden DM (2004) Drug-induced prolongation of the QT interval. N Engl J Med 350 (10):1013-1022 (Pubitemid 38269278)
52. Roden DM, Viswanthan PC (2005) Genetics of acquired long QT syndrome. J Clin Invest 115:2025-2032 (Pubitemid 41134138)
53. Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G (2002) A review of the pharmacokinetics tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol 17:1-13 (Pubitemid 34130349)
54. Silver H (2001) Fluvoxamine as an adjunctive agent in schizophrenia. CNS Drug Rev 7:283-304 (Pubitemid 34016086)
55. Silvestre JS, Prous J (2005) Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. J Methods Find Exp Clin Pharmacol 27:289-304 (Pubitemid 41044270)
56. Sinz M, Wallace G, Sahi J (2008) Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical. AAPS J 10:391-400
57. Spina E, de Leon J (2007) Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 100:4-22 (Pubitemid 46051438)
58. Spina E, Santoro V, D'Arrigo C (2008) Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 30:1206-1227
59. Spina E, Scordo MG, D'Arrigo C (2003) Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol 17:517-538 (Pubitemid 37215077)
60. Szegedi A, Anghelescu I, Wiesner J, Schlegel S, Weigmann H, Härtter S, Hiemke C, Wetzel H (1999) Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 32:148-153 (Pubitemid 29434281)
61. Talbot PS, Laruelle M (2002) The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. Eur Neuropsychopharmacol 12:503-511 (Pubitemid 35408701)
62. Talvik M, Nordstrom AL, Larsen NE, Jucaite A, Cervenka S, Halldin C, Farde L (2004) A crossvalidation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration. Psychopharmacology 175:148-153 (Pubitemid 39222344)
63. Tisdale JE, Overholser BR, Wroblewski HA, Sowinski KM, Amankwa K, Borzak S, Kingery JR, Coram R, Zipes DP, Flockhart DA, Kovacs RJ (2011) Enhanced sensitivity to drug-induced QT interval lenthening in patients with heart failure due to left ventricular systolic dysfunction. J Clin Pharmacol 70:16-23
64. Tranulis C, Skalli L, Lalonde P, Nicole L, Stip E (2008) Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature. Drug Saf 31:7-20
65. Unterecker S, Warrings B, Deckert J, Pfuhlmann B (2012) Correlation of QTc intervalprolongation and serum level of citalopram after intoxication - a case report. Pharmacopsychiatry 45:30-34
66. van Noord C, Eijgelsheim M, Stricker BH (2010) Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol 70:16-23
67. Wenzel-Seifert K, Wittmann M, Haen E (2011) QTc prolongation by psychotropic drugs and the risk of Torsades de pointes. Dtsch Ärztebl Int 108:687-693
68. Wong DF, Gründer G, Brasic JR (2007) Brain imaging research: does the science serve clinical practice? Int Rev Psychiatry 19:541-558 (Pubitemid 47493740)
69. Zhou SF (2009) Polymorphims of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet 48:761-804
70. Zhu BT (2010) On the general mechanism of selective induction of cytochrome P450 enzymes by chemicals: some theoretical considerations. Expert Opin Drug Metab Toxicol 6:483-494